Literature DB >> 8541390

Treatment of AIDS-related lymphomas.

J A Sparano1.   

Abstract

Infection with HIV is associated with an increased risk of systemic and primary central nervous system non-Hodgkin's lymphoma. Patients with systemic non-Hodgkin's lymphoma usually present with high- or intermediate-grade histology and extranodal dissemination. Although the prognosis for such patients is poor, some patients clearly benefit from combination chemotherapy, and several new treatment approaches appear promising. Primary central nervous system lymphoma usually occurs in patients with more profound immunosuppression and is associated with a dismal prognosis. Selected patients with good performance status may benefit from therapy, particularly if opportunistic infections have been few and nondebilitating. Finally, Hodgkin's disease has been reported in patients with HIV infection, particularly in patients with a history of intravenous drug use, and it is more likely to present with advanced-stage disease and unfavorable histology.

Entities:  

Mesh:

Year:  1995        PMID: 8541390

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  3 in total

1.  HIV-related NK/T-cell lymphoma in the brain relapsed during intensive chemotherapy but regressed after chemotherapy discontinuation: the importance of maintaining cellular immunity.

Authors:  Yosuke Nagahata; Aiko Kato; Yukihiro Imai; Takayuki Ishikawa
Journal:  Int J Hematol       Date:  2014-06-18       Impact factor: 2.490

Review 2.  Central nervous system infections in individuals with HIV-1 infection.

Authors:  Arunima Mamidi; Joseph A DeSimone; Roger J Pomerantz
Journal:  J Neurovirol       Date:  2002-06       Impact factor: 2.643

3.  Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma.

Authors:  J A Sparano; P H Wiernik; X Hu; C Sarta; D H Henry; H Ratech
Journal:  Med Oncol       Date:  1998-04       Impact factor: 3.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.